Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · IEX Real-Time Price · USD
33.56
+1.09 (3.36%)
At close: Apr 26, 2024, 4:00 PM
30.24
-3.32 (-9.89%)
After-hours: Apr 26, 2024, 6:26 PM EDT

Spyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current20232022202120202019201820172016
Market Capitalization
1,21387282343772211799058
Market Cap Growth
-214.86%-88.19%-37.90%70.36%23.39%99.32%54.12%-
Enterprise Value
874-252-2514423515310540-5
PE Ratio
-0.26-0.26-0.33-3.56-4.66-2.83-4.05-3.31-2.69
PS Ratio
1369.3398.3411.8812.50--46.1617.3012.62
PB Ratio
6.590.470.552.792.703.692.661.790.93
P/FCF Ratio
-0.88-0.88-0.35-4.32-4.71-3.30-5.50-3.57-3.07
P/OCF Ratio
-0.87-0.87-0.35-4.36-4.98-3.37-5.58-3.66-3.10
EV/Sales Ratio
986.03-284.95-10.727.70--27.007.64-1.10
EV/EBITDA Ratio
0.750.750.30-2.27-2.96-1.98-2.38-1.470.24
EV/EBIT Ratio
0.750.750.30-2.20-2.90-1.96-2.37-1.460.23
EV/FCF Ratio
2.542.540.31-2.66-2.93-2.28-3.22-1.580.27
Debt / Equity Ratio
--0.090.060.040.08---
Debt / EBITDA Ratio
---0.06-0.08-0.07-0.07---
Debt / FCF Ratio
---0.06-0.09-0.07-0.08---
Quick Ratio
10.6210.623.934.759.014.007.289.4816.32
Current Ratio
10.6810.684.254.919.114.067.499.7716.75
Asset Turnover
0.000.000.030.14000.060.090.07
Return on Equity (ROE)
576.40%576.40%-127.10%-61.40%-68.70%-88.00%-71.40%-48.30%-48.60%
Return on Assets (ROA)
-160.40%-160.40%-95.10%-47.90%-58.30%-72.90%-63.70%-44.50%-34.40%
Return on Capital (ROIC)
-131.67%-131.67%-154.33%-73.78%-56.09%-123.32%-67.42%-54.98%-34.79%
Earnings Yield
-27.92%-388.82%-302.87%-28.09%-21.44%-35.34%-24.71%-30.25%-37.14%
FCF Yield
-8.20%-114.12%-289.74%-23.17%-21.22%-30.34%-18.17%-28.02%-32.61%
Buyback Yield / Dilution
-104.59%-104.59%-28.19%-23.18%-67.05%-53.44%-37.64%-54.50%-1532.50%
Total Shareholder Return
-104.59%-104.59%-28.19%-23.18%-67.05%-53.44%-37.64%-54.50%-1532.50%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).